von Mehren M, Benjamin RS, Bui MM et al.. NCCN Clinical Practice Guidelines in Oncology: Soft Tissue Sarcoma. Version 2, 2012. Available at NCCN.org. Accessed June 26, 2012.
Pollack A, Zagars GK, Goswitz MS et al.. Preoperative vs. postoperative radiotherapy in the treatment of soft tissue sarcomas: a matter of presentation. Int J Radiat Oncol Biol Phys 1998;42:563–572.
Hohenberger P, Schwarzbach MH. Management of locally recurrent soft tissue sarcoma after prior surgery and radiation therapy. Recent Results Cancer Res 2009;179:271–283.
Bokemeyer C, Franzke A, Hartmann JT et al.. A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas. Cancer 1997;80:1221–1227.
Wunder JS, Nielsen TO, Maki RG et al.. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 2007;8:513–524.
Suppiah R, Wood L, Elson P et al.. Phase I/II study of docetaxel, ifosfamide, and doxorubicin in advanced, recurrent, or metastatic soft tissue sarcoma (STS). Invest New Drugs 2006;24:509–514.
Watanabe T, Tsuda M, Tanaka S et al.. Adaptor protein Crk induces Src-dependent activation of p38 MAPK in regulation of synovial sarcoma cell proliferation. Mol Cancer Res 2009;7:1582–1592.
Mortenson MM, Khatri VP, Bennett JJ et al.. Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal. Surg Oncol Clin N Am 2007;16:177–197.